Human T cells efficiently control RSV infection
Respiratory syncytial virus (RSV) infection causes significant morbidity and mortality in infants, immunocompromised individuals, and older individuals. There is an urgent need for effective antivirals and vaccines for high-risk individuals. We used 2 complementary in vivo models to analyze RSV-associated human lung pathology and human immune correlates of protection. RSV infection resulted in widespread human lung epithelial damage, a proinflammatory innate immune response, and elicited a natural adaptive human immune response that conferred protective immunity. We demonstrated a key role for human T cells in controlling RSV infection. Specifically, primed human CD8+ T cells or CD4+ T cells effectively and independently control RSV replication in human lung tissue in the absence of an RSV-specific antibody response. These preclinical data support the development of RSV vaccines, which also elicit effective T cell responses to improve RSV vaccine efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
JCI insight - 8(2023), 11 vom: 08. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De, Chandrav [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive immunity |
|---|
| Anmerkungen: |
Date Completed 09.06.2023 Date Revised 23.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1172/jci.insight.168110 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356622746 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356622746 | ||
| 003 | DE-627 | ||
| 005 | 20231226070843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/jci.insight.168110 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356622746 | ||
| 035 | |a (NLM)37159271 | ||
| 035 | |a (PII)e168110 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De, Chandrav |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human T cells efficiently control RSV infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2023 | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Respiratory syncytial virus (RSV) infection causes significant morbidity and mortality in infants, immunocompromised individuals, and older individuals. There is an urgent need for effective antivirals and vaccines for high-risk individuals. We used 2 complementary in vivo models to analyze RSV-associated human lung pathology and human immune correlates of protection. RSV infection resulted in widespread human lung epithelial damage, a proinflammatory innate immune response, and elicited a natural adaptive human immune response that conferred protective immunity. We demonstrated a key role for human T cells in controlling RSV infection. Specifically, primed human CD8+ T cells or CD4+ T cells effectively and independently control RSV replication in human lung tissue in the absence of an RSV-specific antibody response. These preclinical data support the development of RSV vaccines, which also elicit effective T cell responses to improve RSV vaccine efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Adaptive immunity | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Mouse models | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a Virology | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Pickles, Raymond J |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Wenbo |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Baolin |e verfasserin |4 aut | |
| 700 | 1 | |a Boone, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Mingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Battaglia, Diana M |e verfasserin |4 aut | |
| 700 | 1 | |a Askin, Frederic B |e verfasserin |4 aut | |
| 700 | 1 | |a Whitmire, Jason K |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestri, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, J Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Wahl, Angela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCI insight |d 2016 |g 8(2023), 11 vom: 08. Juni |w (DE-627)NLM257703918 |x 2379-3708 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:11 |g day:08 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/jci.insight.168110 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 11 |b 08 |c 06 | ||